ORIGINAL RESEARCH article
Front. Cardiovasc. Med.
Sec. Cardiovascular Genetics and Systems Medicine
Characterization of the R893C NaV1.5 mutation in Brugada Syndrome
Szabolcs Gaal 1
Beata Meszaros 2
Julianna Volko 2
Noemi Bilakovics 2
Umair Naseem Muhammad 2
Zoltán Pethő 3
Gabor Sandorfi 1
Gabor Menko 2
Orsolya Voros 2
Istvan Balogh 4
Gyorgy Panyi 2
Zoltan Csanadi 1
Tibor Gabor Szanto 2
1. Division of Cardiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, Debrecen, Hungary
2. Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
3. Institute of Physiology II, University of Münster, Münster, Germany, Munster, Germany
4. University of Debrecen, Department of Human Genetics, Debrecen, Hungary, Debrecen, Hungary
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract
Brugada syndrome (BrS) is a genetically determined cardiac arrhythmogenic syndrome with increased risk of sudden cardiac death. BrS is mostly caused by mutations in SCN5A gene encoding the primary a-subunit of the cardiac sodium channel NaV1.5. We aimed at characterizing the functional alterations caused by the R893C mutation, identified in a proband diagnosed with BrS, and establishing whether the mutation is associated with BrS. Although several mutations have been reported in the close vicinity of R893, the functional role of this region remains unknown and, in addition, exploring SCN5A mutations in patients with inherited arrhythmogenic syndromes is critical for understanding the pathogenesis of arrhythmias. Patch clamp recordings have demonstrated that R893C almost completely abolished the sodium current, INa, though the mutation did not exert dominant-negative effect on wild-type NaV1.5 channels. We also observed significant decrease in channel activation and a depolarized shift of steady–state inactivation curve, however, the kinetics of inactivation and recovery from fast inactivation were not changed by the mutation. Moreover, the reducing agent Dithiotreitol partially restored the normal function of NaV1.5 in the R893C mutant highlighting a likely mechanism for loss of conduction via formation of disulphide bridges. We showed that R893H channels also failed to produce any detectable INa that confirms the importance of the highly conserved R893 in gating. Our study reveals R893C is a loss-of-function mutation with altered electrophysiological characteristics of NaV1.5. Thus, R893C may contribute to the BrS phenotype of the proband. Our findings may facilitate the understanding of the mechanisms of arrhythmogenesis in BrS, as it helps to identify mutational hotspots in BrS. Moreover, our work may improve novel gene therapy and new therapeutic drug design targeting NaV1.5 channelopathies.
Summary
Keywords
Arginine5, Brugada syndrome1, DTT reagent4, gating3, loss-of-function2
Received
16 October 2025
Accepted
04 February 2026
Copyright
© 2026 Gaal, Meszaros, Volko, Bilakovics, Muhammad, Pethő, Sandorfi, Menko, Voros, Balogh, Panyi, Csanadi and Szanto. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Tibor Gabor Szanto
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.